CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc. entered into a securities purchase agreement with accredited investors for a $14 million private placement, issuing 2,867,089 common shares at $4.883 per share, a 5% discount to the March 16 closing price. The company plans to use the cash for sales and marketing, R&D, general corporate purposes and working capital.
CapsoVision reported preliminary, unaudited revenue of $3.9 million for the fourth quarter of 2025 and $13.6 million for full year 2025, with approximately $10.1 million in cash, cash equivalents, restricted cash and investments as of December 31, 2025.
The company decided not to pursue FDA clearance for its first-generation CapsoCam Colon capsule after 510(k) feedback, and is prioritizing a second-generation version supported by an expanded pivotal study targeting about 800 patients, with over 500 enrolled and a planned 510(k) submission in the third quarter of 2026. CapsoVision is also developing a pancreatic cancer screening application using its CapsoCam UGI system; an initial Breakthrough Device Designation request was not approved, and the company expects to resubmit after a planned study of about 90 patients starting in the second quarter of 2026.
CapsoVision, Inc. amended its development agreement with Canon Inc. for CMOS image sensors, increasing the total fee by $1 million to reflect enhanced specifications. This raises the original approximately $4.1 million commitment, increasing the remaining development fee that will be paid through sensor purchase pricing. The amendment keeps the defined Additional Amount unchanged and confirms that all other terms, including the structure for future sensor purchases and clinical and FDA 510(k) objectives, remain in full force and effect.
CapsoVision, Inc director Tsai Chen Lung reported an open-market purchase of common stock. A joint brokerage account for Tsai and his wife bought 20 shares of CapsoVision common stock at $4.17 per share on July 3, 2025. This Form 4/A is an amendment, filed because the transaction was inadvertently omitted from the original Form 4 submitted on July 7, 2025. After this trade, the account held 20 shares directly.
CapsoVision, Inc. reported higher Q3 results but remained unprofitable. Net revenue for the three months ended September 30, 2025 was $3.538 million versus $2.966 million a year ago, with gross profit of $1.914 million. Operating expenses rose to $9.933 million, driving a quarterly net loss of $7.921 million and a nine‑month net loss of $17.921 million. Cash and cash equivalents were $17.787 million as of September 30, 2025.
The company completed an IPO in July 2025, raising approximately $23.37 million in net proceeds and converting all preferred stock into common shares after a 1‑for‑3.33 reverse split. Management disclosed that current conditions “raise substantial doubt” about the ability to continue as a going concern. CapsoVision also entered a $4.1 million development agreement with Canon for CMOS sensors, paying $1.0 million at effectiveness and carrying an outstanding purchase commitment of $2.5 million. Revenue was driven mainly by U.S. product sales, while service revenue included cloud delivery and physician reading services.
CapsoVision, Inc. furnished a current report announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information under Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. CapsoVision’s common stock trades on Nasdaq under the symbol CV.
CapsoVision, Inc. reported that it issued a press release announcing a 510(k) FDA application for Breakthrough Device Designation for its Pancreatic Cancer Screening Capsule. The disclosure was furnished under Item 8.01 and includes the press release as Exhibit 99.1 dated November 10, 2025.
This notice signals a regulatory step only; it does not reflect FDA clearance or authorization. The company did not disclose financial terms or operational changes in this update.
CapsoVision (CV) reported a Form 4 for David Garcia, Sr. VP of Finance. On 11/03/2025, he received a stock option grant for 165,000 shares at an exercise price of $4.78 per share, expiring 11/03/2035. The filing lists ownership of these derivative securities as direct.
The options vest as to 25% on November 3, 2026, with the remaining 75% vesting in 36 equal monthly installments through November 3, 2029, contingent on continued service.
CapsoVision, Inc. (CV) filed a Form 3 for an officer reporting no holdings. On 11/03/2025, Senior Vice President of Finance David Garcia submitted an initial statement of beneficial ownership indicating no securities are beneficially owned.
The filing was executed via Power of Attorney by Kang-Huai (Johnny) Wang. This is an administrative disclosure under Section 16 and does not reflect a transaction or change in ownership.
CapsoVision, Inc. appointed David Garcia as principal financial officer and principal accounting officer, effective November 3, 2025. Garcia brings more than 20 years of finance leadership experience, most recently serving as VP of Financial Planning and Analysis at Matterport from October 2020 to October 2025, with prior senior roles at View, Intelepeer, and Align Technology.
His compensation includes a $300,000 annual base salary, an option to purchase 165,000 shares granted on November 3, 2025 at the closing share price that day, and a $12,500 quarterly bonus. Vesting is structured with 25% on November 3, 2026, and the remainder in 36 equal monthly installments thereafter. The company entered into its standard indemnification agreement with Garcia. The company reported no arrangements leading to his appointment and no related-party relationships under Item 404(a). A press release announcing the appointment was furnished as Exhibit 99.1.
CapsoVision, Inc. reported that Rebecca Petersen plans to retire as Senior Director of Clinical Affairs effective October 15, 2025, and that Keri Jorgenson has been promoted to Director of Clinical Operations to take over responsibility for clinical development operations with the existing team. The company states it does not anticipate any disruption to its clinical development work during this transition. To support a smooth handover, Ms. Petersen will provide consulting services starting October 16, 2025 under an hourly arrangement of $150 per hour, with either party able to terminate the agreement on three days’ notice, and her unvested stock options will continue to vest according to their current schedule.